WO2007059715A3 - Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus - Google Patents

Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus Download PDF

Info

Publication number
WO2007059715A3
WO2007059715A3 PCT/CU2006/000015 CU2006000015W WO2007059715A3 WO 2007059715 A3 WO2007059715 A3 WO 2007059715A3 CU 2006000015 W CU2006000015 W CU 2006000015W WO 2007059715 A3 WO2007059715 A3 WO 2007059715A3
Authority
WO
WIPO (PCT)
Prior art keywords
flaviviruses
dengue virus
serotypes
prophylactic
therapeutic treatment
Prior art date
Application number
PCT/CU2006/000015
Other languages
English (en)
French (fr)
Other versions
WO2007059715A2 (es
WO2007059715A8 (es
Inventor
Santiago Glay Chinea
Galindo Vivian Huerta
Dunn Alejandro Miguel Martin
Cowley Jorge Victor Gavilondo
Salazar Noralvis Fleitas
Cruz Osmany Guirola
Valdes Jeovanis Gil
Morales Aida Zulueta
Cruz Lisset Hermida
Avila Marta Ayala
Roche Diamile Gonzalez
Meireles Rolando Paez
Mayora Patricia Gabriel Toledo
Nunez Monica Sarria
Lasa Alexis Musacchio
Reyes Yuliet Mazola
Original Assignee
Ct Ingenieria Genetica Biotech
Santiago Glay Chinea
Galindo Vivian Huerta
Dunn Alejandro Miguel Martin
Cowley Jorge Victor Gavilondo
Salazar Noralvis Fleitas
Cruz Osmany Guirola
Valdes Jeovanis Gil
Morales Aida Zulueta
Cruz Lisset Hermida
Avila Marta Ayala
Roche Diamile Gonzalez
Meireles Rolando Paez
Mayora Patricia Gabriel Toledo
Nunez Monica Sarria
Lasa Alexis Musacchio
Reyes Yuliet Mazola
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech, Santiago Glay Chinea, Galindo Vivian Huerta, Dunn Alejandro Miguel Martin, Cowley Jorge Victor Gavilondo, Salazar Noralvis Fleitas, Cruz Osmany Guirola, Valdes Jeovanis Gil, Morales Aida Zulueta, Cruz Lisset Hermida, Avila Marta Ayala, Roche Diamile Gonzalez, Meireles Rolando Paez, Mayora Patricia Gabriel Toledo, Nunez Monica Sarria, Lasa Alexis Musacchio, Reyes Yuliet Mazola filed Critical Ct Ingenieria Genetica Biotech
Priority to JP2008541574A priority Critical patent/JP2009524581A/ja
Priority to US12/094,503 priority patent/US20090312190A1/en
Priority to CA002630629A priority patent/CA2630629A1/en
Priority to EP06817996A priority patent/EP1958959A2/en
Priority to AU2006317350A priority patent/AU2006317350A1/en
Priority to BRPI0618865-6A priority patent/BRPI0618865A2/pt
Publication of WO2007059715A2 publication Critical patent/WO2007059715A2/es
Publication of WO2007059715A3 publication Critical patent/WO2007059715A3/es
Publication of WO2007059715A8 publication Critical patent/WO2007059715A8/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención está relacionada con la industria farmacéutica, se describe un área conservada de la superficie de la proteína E, empleable en el desarrollo de moléculas de amplio espectro útiles en la prevención y/o tratamiento de las infecciones por virus dengue 1-4 y otros flavivirus. Además la presente invención se relaciona con proteínas quiméricas para uso como vacunas y tratamiento profiláctico y terapéutico contra los cuatro serotipos del virus de dengue y otros flavivirus.
PCT/CU2006/000015 2005-11-22 2006-11-21 Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus WO2007059715A2 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2008541574A JP2009524581A (ja) 2005-11-22 2006-11-21 デング熱ウイルスの４種の血清型及び他のフラビウイルス属の予防的処置及び／又は治療的処置のための方法及びタンパク質
US12/094,503 US20090312190A1 (en) 2005-11-22 2006-11-21 Methods and Proteins for the Prophylactic and/or Therapeutic Treatment of Four Serotypes of Dengue Virus and Other Flaviviruses
CA002630629A CA2630629A1 (en) 2005-11-22 2006-11-21 Methods and proteins for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses
EP06817996A EP1958959A2 (en) 2005-11-22 2006-11-21 Methods and proteins for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses
AU2006317350A AU2006317350A1 (en) 2005-11-22 2006-11-21 Methods and proteins for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses
BRPI0618865-6A BRPI0618865A2 (pt) 2005-11-22 2006-11-21 área topográfica e altamente conservada, moléculas, ácido nucleico, proteìna, anticorpos, célula hospedeira, composição farmacêutica, e, método

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2005-0229 2005-11-22
CU20050229A CU23586A1 (es) 2005-11-22 2005-11-22 Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus

Publications (3)

Publication Number Publication Date
WO2007059715A2 WO2007059715A2 (es) 2007-05-31
WO2007059715A3 true WO2007059715A3 (es) 2007-10-18
WO2007059715A8 WO2007059715A8 (es) 2008-02-14

Family

ID=38983663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2006/000015 WO2007059715A2 (es) 2005-11-22 2006-11-21 Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus

Country Status (13)

Country Link
US (1) US20090312190A1 (es)
EP (1) EP1958959A2 (es)
JP (1) JP2009524581A (es)
KR (1) KR20080080137A (es)
CN (1) CN101360758A (es)
AR (1) AR058215A1 (es)
AU (1) AU2006317350A1 (es)
BR (1) BRPI0618865A2 (es)
CA (1) CA2630629A1 (es)
CU (1) CU23586A1 (es)
RU (1) RU2008125077A (es)
WO (1) WO2007059715A2 (es)
ZA (1) ZA200804874B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2031528A4 (en) * 2006-05-26 2009-06-17 Univ Kyoto ESTIMATING A PROTEIN-COMPOUND INTERACTION AND RATIONAL DESIGN OF A LIBRARY OF COMPOUNDS BASED ON CHEMICAL GENOMIC INFORMATION
CU20080028A6 (es) 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus
AU2009305113B2 (en) * 2008-10-13 2015-07-16 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
CN101921310B (zh) * 2009-06-15 2014-03-12 温州医学院 登革病毒特异性hla-a2限制性表位肽及应用
BRPI0904020B8 (pt) * 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
US20130203655A1 (en) * 2010-02-12 2013-08-08 Margaret Kielian Methods for preventing or treating viral infection
CN102906266A (zh) * 2010-05-21 2013-01-30 高等教育联邦系统-匹兹堡大学 登革病毒通用序列及其使用方法
CN102168058B (zh) * 2010-11-30 2013-01-16 湖南师范大学 一种抗肿瘤靶向工程菌和菌剂及其制备方法
CN102824633A (zh) * 2011-06-16 2012-12-19 中国人民解放军军事医学科学院微生物流行病研究所 一种四价登革病毒亚单位疫苗及其制备方法和应用
SG10201606635SA (en) 2012-02-16 2016-10-28 Vlp Therapeutics Llc Virus like particle composition
WO2013151764A1 (en) * 2012-04-02 2013-10-10 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus epitopes
CN104812408A (zh) * 2012-07-24 2015-07-29 赛诺菲巴斯德有限公司 用于防止登革热病毒感染的疫苗组合物
ES2859574T3 (es) * 2012-08-07 2021-10-04 Massachusetts Inst Technology Anticuerpos de antivirus del dengue y usos de los mismos
CU24188B1 (es) * 2012-12-27 2016-07-29 Ct De Ingeniería Genética Y Biotecnología Composición vacunal contra el virus dengue
CN103116022A (zh) * 2013-01-23 2013-05-22 广西壮族自治区兽医研究所 快速检测猪乙型脑炎抗体试纸条及其制备方法
KR20160005345A (ko) * 2013-05-07 2016-01-14 에프. 호프만-라 로슈 아게 삼량체성 항원 결합 분자
KR20160027019A (ko) * 2013-06-26 2016-03-09 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 뎅기 바이러스 백신에 대한 방법 및 조성물
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
SG11201606624WA (en) 2014-02-11 2016-09-29 Visterra Inc Antibody moleules to dengue virus and uses thereof
BR112016017764A2 (pt) 2014-02-11 2017-10-10 Massachusetts Inst Technology anticorpo antidengue de amplo espectro
CU20140026A7 (es) * 2014-03-03 2015-11-27 Ct De Ingeniería Genética Y Biotecnología Biocubafarma Péptidos horquilla beta con propiedades antivirales contra el virus dengue
TWI720946B (zh) 2014-08-08 2021-03-11 美商Ｖｌｐ醫療股份有限公司 包含改質套膜蛋白質ｅ３之類病毒粒子
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
EP3188751A1 (en) 2014-09-02 2017-07-12 Sanofi Pasteur Vaccine compositions against dengue virus diseases
US10098943B2 (en) 2014-09-11 2018-10-16 Vlp Therapeutics, Llc Flavivirus virus like particle
JP6602875B2 (ja) * 2015-01-26 2019-11-06 マクロジェニクス，インコーポレーテッド Ｄｒ５結合ドメインを含む多価分子
US10487120B2 (en) * 2015-02-09 2019-11-26 Academia Sinica Epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
WO2017165736A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulation of antibody molecules to dengue virus
GB201610162D0 (en) * 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
SG10201607778XA (en) * 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2019069130A1 (en) 2017-10-05 2019-04-11 Sanofi Pasteur COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE
CA3091047A1 (en) * 2018-02-14 2019-08-22 Yale University Compositions for modulation of a trem or treml protein and methods of use
KR102301130B1 (ko) * 2018-12-27 2021-09-15 주식회사 이뮨메드 뎅기출혈열 진단 키트
CN110007067A (zh) * 2019-03-11 2019-07-12 江苏理工学院 一种蛋白质分子对接检测装置
CN110568190A (zh) * 2019-08-30 2019-12-13 深圳国际旅行卫生保健中心 登革热病毒抗原、检测试剂、检测试纸、检测试剂盒及其使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023754A1 (es) * 1996-11-25 1998-06-04 Centro De Ingenieria Genetica Y Biotecnologia (Cigb) Procedimiento para la expresion de genes de los virus del dengue
WO2004052293A2 (en) * 2002-12-11 2004-06-24 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
WO2005002501A2 (en) * 2003-04-22 2005-01-13 Children's Medical Center Corporation Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
EP0951555A2 (en) 1996-09-24 1999-10-27 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
JP4504464B2 (ja) 1997-02-28 2010-07-14 サノフィ パスツール バイオロジクス カンパニー キメラフラビウイルスワクチン
JP2001511459A (ja) 1997-07-31 2001-08-14 ハワイ バイオテクノロジー グループ， インコーポレイテッド フラビウイルス感染に対抗する組換え二量体エンベロープワクチン
AU754386B2 (en) 1997-09-23 2002-11-14 Bavarian Nordic A/S Dengue virus antigens and treatment of dengue fever
ATE471983T1 (de) 1998-09-02 2010-07-15 Us Gov Health & Human Serv Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
BRPI0613287A2 (pt) * 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023754A1 (es) * 1996-11-25 1998-06-04 Centro De Ingenieria Genetica Y Biotecnologia (Cigb) Procedimiento para la expresion de genes de los virus del dengue
WO2004052293A2 (en) * 2002-12-11 2004-06-24 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
WO2005002501A2 (en) * 2003-04-22 2005-01-13 Children's Medical Center Corporation Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EBI [online] 1 October 2003 (2003-10-01), SHU L & ZUO L: "no title", XP002430600, retrieved from UNIPROT/TREMBL accession no. Q7TLC5 Database accession no. Q7TLC5 *
GONCALVEZ ANA P ET AL: "Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 78, no. 23, December 2004 (2004-12-01), pages 12919 - 12928, XP002338600, ISSN: 0022-538X *
MASON PW ET AL.: "The antigenic structure of dengue type 1 virus envelope and NS1 proteins expressed in Escherichia coli", JOURNAL OF GENERAL VIROLOGY, vol. 71, no. 9, September 1990 (1990-09-01), pages 2107 - 2114, XP002430578, ISSN: 0022-1317 *
MOTA J ET AL: "Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 23, no. 26, 16 May 2005 (2005-05-16), pages 3469 - 3476, XP004852137, ISSN: 0264-410X *
THULLIER P ET AL: "A recombinant Fab neutralizes dengue virus in vitro", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 69, no. 2-3, 15 April 1999 (1999-04-15), pages 183 - 190, XP004168126, ISSN: 0168-1656 *

Also Published As

Publication number Publication date
ZA200804874B (en) 2009-04-29
US20090312190A1 (en) 2009-12-17
KR20080080137A (ko) 2008-09-02
RU2008125077A (ru) 2009-12-27
CU23586A1 (es) 2010-10-30
EP1958959A2 (en) 2008-08-20
JP2009524581A (ja) 2009-07-02
WO2007059715A2 (es) 2007-05-31
CN101360758A (zh) 2009-02-04
AU2006317350A1 (en) 2007-05-31
AR058215A1 (es) 2008-01-23
BRPI0618865A2 (pt) 2011-09-13
CA2630629A1 (en) 2007-05-31
WO2007059715A8 (es) 2008-02-14

Similar Documents

Publication Publication Date Title
WO2007059715A8 (es) Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
WO2007081974A3 (en) Viral hepatitis treatment
WO2005087731A8 (en) Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2005087725A3 (en) Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2005087721A3 (en) Compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2008124148A3 (en) Sulfur compounds as inhiibitors of hepatitis c virus ns3 serine protease
ECSP066626A (es) Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
WO2007021672A3 (en) Vaccination against dengue virus infection
WO2007008657A3 (en) Hepatitis c virus inhibitors
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
EA201001322A1 (ru) Вакцины против хламидиоза
NO20064584L (no) Tetrahydropyridoindolderivater
WO2009008913A3 (en) P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
MX2010004704A (es) Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c.
WO2005074904A3 (en) Silinane compounds as cysteine protease inhibitors
DE602006014720D1 (de) Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
WO2012061248A3 (en) Novel specific hcv ns3 protease inhibitors
WO2006102243A3 (en) Alpha ketoamide compounds as cysteine protease inhibitors
ATE424823T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate als arzneimittel zur behandlung von unfruchtbarkeit
ATE406895T1 (de) 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin- derivate als arzneimittel zur behandlung von unfruchtbarkeit
WO2013012835A3 (en) Sirna useful in the treatment of flavivirus infection
WO2006102535A3 (en) Sulfonyl containing compounds as cysteine protease inhibitors
IL190464A0 (en) Cyclic n-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
WO2008051448A3 (en) Methods and compositions for efficient removal of protein a from binding molecule preparations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/006703

Country of ref document: MX

Ref document number: 2008541574

Country of ref document: JP

Ref document number: 2630629

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 4720/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006317350

Country of ref document: AU

Ref document number: 1020087015049

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008125077

Country of ref document: RU

Ref document number: 2006817996

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006317350

Country of ref document: AU

Date of ref document: 20061121

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006317350

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200680051377.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006817996

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12094503

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0618865

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080521